Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: fluocinolone acetonide Clear all
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 28, 2026, 10:42 AM EDT
Not listed Phase 4 Interventional

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

NCT05322070
View directory record Official record
Conditions
Uveitis, Posterior
Interventions
Fluocinolone Acetonide Intravitreal Implant 0.18 mg
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Fullerton, California • Glendale, California • Pasadena, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082
View directory record Official record
Conditions
Noninfectious Posterior Uveitis
Interventions
fluocinolone acetonide intravitreal implant, Fluocinolone acetonide 2.1mg
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Sep 28, 2026, 10:42 AM EDT
Completed No phase listed Observational

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

NCT01060787
View directory record Official record
Conditions
Inflammation, Uveitis
Interventions
Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg
Procedure
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
6 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Sep 28, 2026, 10:42 AM EDT
Terminated Phase 2 Interventional Results available

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

NCT00770770
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis

NCT01469767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Fluocinonide cream
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 4 Interventional

Assessment of Atrophogenic Potential of Triple Combination Cream for Treatment of Melasma

NCT00469183
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema

NCT00490815
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 28, 2026, 10:42 AM EDT
Terminated Phase 4 Interventional Results available

Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma

NCT00669071
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, Cetaphil® Moisturizing Cream as Inactive Control
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 74 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
La Jolla, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Sep 28, 2026, 10:42 AM EDT
Recruiting Phase 3 Interventional

Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

NCT05844982
View directory record Official record
Conditions
Radiation Retinopathy, Visual Impairment
Interventions
Faricimab, fluocinolone acetonide
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
27
States / cities
Palo Alto, California • Manchester, Connecticut • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 10:42 AM EDT
Completed No phase listed Observational

Cutaneous Lupus Medication Experience Study

NCT02176148
View directory record Official record
Conditions
Cutaneous Lupus
Interventions
fluocinonide 0.05% cream
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
12 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 3 Interventional Results available

Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema

NCT00344968
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Fluocinolone Acetonide, Standard of care laser photocoagulation
Drug · Procedure
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 28, 2026, 10:42 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration

NCT00032396
View directory record Official record
Conditions
Macular Degeneration
Interventions
Retisert Implant
Drug
Lead sponsor
Control Delivery Systems
Industry
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2006 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 1 Interventional

Fluocinolone Implant to Treat Macular Degeneration

NCT00008515
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 28, 2026, 10:42 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

NCT06536491
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
EC-104 high dose, EC-104 low dose, Dexamethasone intravitreal implant
Drug
Lead sponsor
Eclipse Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional

Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO)

NCT00636493
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
fluocinolone acetonide (Retisert Implant)
Device
Lead sponsor
Glenn Jaffe
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 2 Interventional Results available

The MAP Study: Fluocinolone Acetonide (FA)/Medidur (TM) for Age Related Macular Degeneration (AMD) Pilot

NCT00605423
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Fluocinolone Acetonide/Medidur
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2014 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Using an Internet Study to Improve Adherence for Psoriasis Patients

NCT01802580
View directory record Official record
Conditions
Psoriasis
Interventions
Internet Survey, fluocinonide 0.05% ointment
Behavioral · Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 28, 2026, 10:42 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

NCT00472966
View directory record Official record
Conditions
Melasma
Interventions
Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 28, 2026, 10:42 AM EDT